Phase I study of intratumoral injection of HF10, naturally occurring mutant of herpes simplex virus type 1 - Intratumoral injection of naturally occurring mutant of HSV-1

Mie University Graduate School of Medicine0 个研究点目标入组 9 人开始时间: 2012年2月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Past history of severe hypersensitivity. 2) Positive for HBs antigen, HCV antibody or HIV antibody. 3) Experience of autoimmune disease requiring treatment during 6 months prior to consent. 4) Active multiple primary malignancy. 5) With lesions, such as visceral metastases or bone metastases, which need emergent therapies. 6) Use of anti-HSV drugs. 7) Use of steroids or immune-suppressive drugs. 8) Patients with severe complications. 9) Presence of central nervous system metastasis. 10) Lesion to be treated: high risk of bleeding. 11) Lesion to be treated: high risk of penetration or perforation. 12) Use of anti-platelet drugs or difficult to cessation of them. 13) Use of anticoagulant which is unsafe for intratumoral injection. 14) Pregnant or breastfeeding. 15) Patients who deny contraception during this study. 16) Any other cases that the attending doctor judges not appropriate to enroll to this study.

发起方

Mie University Graduate School of Medicine